Processa Pharmaceuticals (PCSA) executive Young received 1,813,133 Restricted Stock Units
Stocks in this Quantisnow insightHealth Care
Insider transactions reported
David Young (Pres. Research & Development at Processa Pharmaceuticals Inc., PCSA) reported that they received 1,813,133 Restricted Stock Units on Jul 24, 2025.
- Reporting person
- Young David
- Role
- Pres. Research & Development
Options and other derivatives
| Date | Type | Security | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|
| Jul 24, 2025 | Grant or award (A) | Restricted Stock UnitsOn 1,813,133 Common Stock1, 2 | +1,813,133 | - | - | 1,821,016 direct |
Holdings before and after
- Restricted Stock Units: 7,883 to 1,821,016 direct
Footnotes from the filing
- 1. Restricted stock granted under the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan ( Omnibus Plan ), of which 1,790,833 shares are subject to stockholder approval of the revised Omnibus Plan.
- 2. Each Restricted Stock Unit represents a contingent right to receive one share of the Issuer's common stock, following its vesting on of one-third on January 1, 2026, and one-thirty-sixth each month thereafter until fully vested on January 1, 2028.
Transaction codes in this filing
- Grant or award:
- Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
FAQ
What did Young report in this PCSA Form 4?
David Young (Pres. Research & Development at Processa Pharmaceuticals Inc., PCSA) reported that they received 1,813,133 Restricted Stock Units on Jul 24, 2025.
What does transaction code A mean on an SEC Form 4?
Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.
Historical context for PCSA
Earlier insider filings at PCSA
- Jul 28, 2025SEC Form 4 filed by Chief Executive Officer Ng George K
- Jul 28, 2025SEC Form 4 filed by Director Neal James R
- Jul 28, 2025SEC Form 4 filed by Director Baluch Khoso
- Jul 28, 2025SEC Form 4 filed by Director Pannu Geraldine
- Jul 28, 2025SEC Form 4 filed by Director Yorke Justin W
Keep researching PCSA
- PCSA insider tradesEvery buy and sale reported by Processa Pharmaceuticals Inc. officers, directors and large holders.
- What is Form 4?The SEC filing that reports a change in an insider's holdings, such as a purchase, sale, option exercise or grant, generally within two business days.
- Form 4 explainedForm 4 is the SEC filing that discloses when officers, directors and 10% owners buy or sell company stock, due within 2 business days. Learn every key field and code.
- Insider trading trackerThe latest insider buys and sales across every stock.
- PCSA financial statementsRevenue, profit, cash flow and balance sheet from Processa Pharmaceuticals Inc.'s SEC filings.
Quantisnow market dataNASDAQ
PCSA
Processa Pharmaceuticals Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for PCSA
Full PCSA profile on Quantisnow Follow PCSA and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time